Hybridoma technology: is it still useful?

Area of Science:

• Immunotechnology
• Biotechnology
• Antibody Engineering

Background:

• Hybridoma technology, based on fusing B lymphocytes with myeloma cells, enabled the isolation of monoclonal antibodies (mAbs).
• mAbs are crucial for therapeutic, diagnostic, and research applications.
• Despite its significance, hybridoma technology faces challenges like low fusion efficiency and reliance on animal models.

Purpose of the Study:

• To review the foundational hybridoma technology for monoclonal antibody generation.
• To discuss emerging antibody isolation technologies and their advantages.
• To evaluate the current relevance and limitations of hybridoma-based strategies.

Main Methods:

• Review of hybridoma technology principles and limitations.
• Exploration of alternative antibody generation methods, including phage display and single B cell technologies.
• Comparative analysis of different mAb isolation approaches.

Main Results:

• Hybridoma technology, while foundational, suffers from inefficiencies and ethical concerns regarding animal use.
• Newer techniques like antibody phage display and single B cell isolation offer improved efficiency and reduced animal dependency.
• The choice of method depends on specific application needs and desired antibody characteristics.

Conclusions:

• Hybridoma technology remains a valuable tool but is increasingly complemented by advanced methods.
• Emerging technologies provide more efficient and versatile platforms for monoclonal antibody discovery.
• Continued innovation in antibody generation is essential for advancing biomedical research and therapeutics.